entertainment -WSS

entertainment

author：fashion 2025-09-29 21:25:30 - browse：54397

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Why health records don't always know when patients are dead

entertainment

WSS

Study identifies new proteins linked to dementia risk 25 years later

Virtual care provider acquires bankrupt Pear's prescription apps

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Violet CEO on training clinicians to promote more inclusive care

Tesla recalling nearly 16,000 of its 2021

What STAT readers think about the FDA and patient advocacy

explore

entertainment

focus

The cancer drug shortage isn’t new — and neither are the solutions

I learned firsthand about improving diversity in clinical trials

23andMe had bad news about my health. I wish a person had delivered it

Stanford president's case begs question: Who takes blame?

Medicare details structure of new drug price negotiation program

Stanford president's case begs question: Who takes blame?

Affirmative action in medical school literally saved lives

What STAT readers think about the FDA and patient advocacy

Virginia high school admissions case could be legal follow

Vir antibody drug aimed at influenza A fails in clinical trial

hotspot

Stanford president faces new allegations over 1999 paper

EF3 tornado rips through North Carolina amid extreme weather nationwide

Judge rejects Trump's request to move Stormy Daniels hush

EF3 tornado rips through North Carolina amid extreme weather nationwide

Affordable Connectivity Program vital to health care, experts say

HCA sued by state AG for quality issues at Mission Health

focus

focus

entertainment

hotspot